Short term effect of continuous positive airway pressure on muscle sympathetic nerve activity in patients with chronic heart failure

S Heindl, C Dodt, M Krahwinkel, G Hasenfuss, S Andreas

Abstract

Objective—To test the hypothesis that the short term application of continuous positive airways pressure (CPAP) increases muscle sympathetic nerve activity in patients with congestive heart failure.

Setting—University hospital and tertiary referral centre.

Patients—10 patients with congestive heart failure (New York Heart Association functional class III; mean (SEM) left ventricular ejection fraction 22 (1)% and 10 healthy subjects matched for age, sex, and weight.

Main outcome measurements—Muscle sympathetic nerve activity, assessed by microneurography of the peroneal nerve, blood pressure, heart rate, minute ventilation, transcutaneous oxygen saturation, and end tidal PCO2, were measured during normal breathing, mask breathing, and CPAP at 5 and 10 cm H2O.

Results—CPAP induced an increase in muscle sympathetic nerve activity and blood pressure in both the patients and the control subjects. In the patients, sympathetic nerve activity increased from 43 (14) bursts/min during mask breathing to 47 (13) bursts/min at CPAP 10 cm H2O (p = 0.03); mean blood pressure increased from 80 (3) mm Hg to 86 (4) mm Hg (p < 0.001). Oxygen saturation improved during CPAP in the patients, from 95.7 (0.6)% to 96.6 (0.7)% (p = 0.004) and remained stable in the control group. There was no effect of CPAP on minute ventilation or heart rate.

Conclusions—In patients with congestive heart failure, short term CPAP elicits sympathetic activation, probably because of unloading of the aortic or cardiopulmonary baroreceptors.

(Heart 2001;85:185–190)

Keywords: heart failure; sympathetic activation; continuous positive airways pressure

Congestive heart failure is an important cause of morbidity and mortality, with limited treatment available. The detrimental role of dysregulation of the autonomic nervous system in congestive heart failure, characterised by sympathetic activation and vagal withdrawal, has been clearly established.12 Concomitant Cheyne-Stokes respiration has been recognised as a sign of poor prognosis, raising the question of the appropriate treatment for this autonomic disturbance.12

Continuous positive airways pressure (CPAP) has been reported to improve cardiac output in acute cardiogenic pulmonary oedema.56 Favourable short term effects of CPAP have also been described in patients with stable congestive heart failure and raised pulmonary capillary wedge pressure.78 There is debate about the effectiveness of CPAP for the treatment of congestive heart failure and concomitant Cheyne-Stokes respiration. While Naughton and colleagues reported an improvement of left ventricular ejection fraction and a reduction in Cheyne-Stokes respiration while on long term CPAP,9 other investigators have not found favourable effects of CPAP in patients with congestive heart failure and Cheyne-Stokes respiration.10–12

The improvement in left ventricular function in patients with congestive heart failure during short term application of CPAP has been attributed to increased intrathoracic pressure and reduced left ventricular transmural pressure, an index of afterload.9 In addition to these haemodynamic effects, it has been suggested that the short term application of CPAP increases heart rate variability and may improve the altered autonomic control of heart rate and cardiac function in congestive heart failure.713 However, increased intrathoracic pressure causes unloading of the aortic or cardiopulmonary baroreceptors and results in increased sympathetic activity.14

Our aim in this study was to investigate the short term effects of nasal CPAP on the sympathetic nervous system by microneurography of the peroneal nerve in patients with congestive heart failure and in healthy subjects. Our objective was to test the hypothesis that the short term application of CPAP would increase sympathetic activity in patients with congestive heart failure.

Methods

SUBJECTS

Patients with congestive heart failure and healthy control subjects were included in our study. Patients with moderate to severe congestive heart failure were eligible if they met the following criteria: age 19–75 years, left ventricular ejection fraction < 35% (gated blood pool), and in stable condition (no rales on auscultation or tibial oedema) on standard cardiac drugs (diuretics, angiotensin converting enzyme (ACE) inhibitors, and glycosides). Patients with congestive heart failure caused by valve disease or those on treatment with
substances which directly influence the sympathetic nervous system (β blockers, central sympathoinhibitory agents) were excluded. Further exclusion criteria were myocardial infarction or pulmonary oedema within six months of entry, significant obstructive lung disease as defined by forced expiratory volume in one second or forced vital capacity < 65% of expected, obesity (body mass index > 28), or a history of obstructive sleep apnoea. We also studied an equal number of control subjects matched for age, sex, and body mass index. We obtained a brief history and performed a physical examination, an ECG, and lung function tests on each control subject. All subjects were healthy non-smokers, and none was on regular drug treatment.

The study was approved by the local ethics committee. Informed written consent was obtained from all patients and control subjects.

MEASUREMENTS

Sympathetic activity was measured using microneurographic recordings of efferent muscle sympathetic nerve activity in the peroneal nerve. This reflects sympathetic discharge to the vascular bed of the skeletal muscle and correlates well with plasma noradrenaline (norepinephrine) concentrations and noradrenaline spillover.

After mapping the course of the peroneal nerve around the head of the fibula by transcutaneous electrical stimulation (Stimuplex HNS 11, B Braun, Melsungen, Germany), a tungsten microelectrode (shaft diameter 200 µm and tip of 1–5 µm) was inserted into the nerve. A reference electrode was inserted subcutaneously 3 cm away. The nerve signals underwent amplification (50 000 times), bandpass filtering (band width of 700–2000 Hz), and passage through a resistance-capacitance integrating network with a time constant of 0.1 second, providing a mean voltage display of sympathetic nerve activity (Nerve Traffic Analysis System, model 662C-3, University of Iowa, Iowa City, USA). The procedure and the criteria for a satisfactory recording of muscle sympathetic nerve activity have been described previously. Sympathetic bursts were identified by inspection of the mean voltage neurogram and quantified as bursts/minute and total activity (total burst amplitude/minute expressed as arbitrary units).

We recorded respiratory rate and tidal volume by respiratory inductive plethysmography (Respitrace Systems, Ambulatory Monitoring Inc, New York, USA), which allows monitoring of respiration without the use of a mouthpiece. Thoracic and abdominal motions that occur with breathing cause changes in the oscillating frequency of circuits within the electronic system of the inductive plethysmograph transducer coils positioned around the rib cage and abdomen. These frequency changes are demodulated to produce output voltage signals. After calibration for volume, the summation signal reflects tidal volume. Heart rate was derived from a continuous recording of the ECG by surface electrodes on the chest. Blood pressure was measured non-invasively by sphygmomanometry (Dinamap XL Monitor, Model 9302, Johnson and Johnson Medical, Arlington, Texas, USA). Arterial oxygen saturation was measured transcutaneously on the tip of the index finger by pulse oximetry (Microspan 3040G, Biochem Int, Wanhessee, Winsconsin, USA), while the end tidal Pco2 was monitored continuously by withdrawing expired gas from the nostrils (Datec Normocap, Helsinki, Finland). In the absence of significant obstructive lung disease, the end tidal CO2 partial pressure correlates closely with arterial CO2 partial pressure.

The mean voltage neurogram, ECG, and respiratory movements were continuously recorded with a paper chart recorder for further manual analysis.

PROTOCOL

Patients and control subjects were studied in the morning, two hours after a low energy breakfast free of beverages containing caffeine. Patients were asked to take their usual drugs except for diuretics, which were withheld on the morning of the study. Before the experiment was begun, patients and control subjects were placed in a supine position and familiarised with breathing through a nasal mask with and without the application of CPAP. After placement of the Respibands around the rib cage and abdomen, calibration of the Respitrace system was performed. The microelectrodes for nerve recordings, the ECG electrodes, the blood pressure cuff, and the sensors for O2 and CO2 measurement were positioned. After a satisfactory nerve signal had been obtained, the protocol started with a 20 minute recording period without a mask (baseline). An open mask with a 3 cm lumen of negligible resistance was then placed over each subject’s nose with the mouth closed for 20 minutes (mask breathing/CPAP 0 cm H2O). Afterwards, CPAP 5 cm H2O and 10 cm H2O were consecutively applied for 20 minutes over the nasal mask, followed by a 20 minute recovery period without CPAP or mask.

DATA ANALYSIS

Data were analysed during the last five minutes of each period, and values for muscle sympathetic nerve activity, heart rate, systolic and diastolic pressures, tidal volume, respiratory rate, oxygen saturation, and end tidal CO2 were averaged over this time. The person interpreting the muscle sympathetic nerve activity recordings was blinded as to whether the subjects were patients or controls and which level of CPAP was used. All variables are given as mean (SEM). Demographic data and baseline values in patients and control subjects were compared with the two tailed paired Student t test. Two way repeated measure analysis of variance (ANOVA) was used to analyse the differences in muscle sympathetic nerve activity, blood pressure, ventilation, and blood gases during mask breathing and CPAP; when ANOVA revealed significance, we performed the paired Student t test and the Bonferroni procedure. Differences in the patients and control subjects are given as percentages referred to the values of mask breathing and...
**Table 1** Demographics and baseline values in patients and control subjects

<table>
<thead>
<tr>
<th></th>
<th>Patients (n=10)</th>
<th>Controls (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>55 (4)</td>
<td>55 (4)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>25 (1)</td>
<td>25 (1)</td>
</tr>
<tr>
<td>Vital capacity (% predicted)</td>
<td>89 (6)</td>
<td>100 (6)</td>
</tr>
<tr>
<td>FEV₁ (% VC)</td>
<td>78 (3)</td>
<td>85 (5)</td>
</tr>
<tr>
<td>Total lung capacity (% predicted)</td>
<td>99 (5)</td>
<td>108 (3)</td>
</tr>
<tr>
<td>MSNA (bursts/min)</td>
<td>43 (4)*</td>
<td>30 (5)</td>
</tr>
<tr>
<td>MSNA/TA (au)</td>
<td>417 (30)*</td>
<td>265 (69)</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>64 (2)</td>
<td>62 (4)</td>
</tr>
<tr>
<td>Mean blood pressure (mm Hg)</td>
<td>80 (6)*</td>
<td>95 (4)</td>
</tr>
<tr>
<td>Respiratory rate (breaths/min)</td>
<td>16 (1)</td>
<td>14 (1)</td>
</tr>
<tr>
<td>Tidal volume (ml)</td>
<td>447 (40)</td>
<td>423 (62)</td>
</tr>
<tr>
<td>Oxygen saturation (%)</td>
<td>95.5 (0.3)</td>
<td>96.0 (0.5)</td>
</tr>
<tr>
<td>P&lt;CO₂ (kPa)</td>
<td>4.80 (0.13)</td>
<td>5.06 (0.13)</td>
</tr>
</tbody>
</table>

Values are mean (SEM).

*p < 0.05 vs control subjects (paired t test).

au, arbitrary units; FEV₁, forced expiratory volume in one second; MSNA, muscle sympathetic nerve activity; P<CO₂, partial pressure of carbon dioxide; TA, total activity.

Results

**SUBJECT CHARACTERISTICS**

The characteristics of the 10 patients and the 10 healthy subjects are shown in table 1. All patients were symptomatic (New York Heart Association functional class III). Two patients and two control subjects were women. Mean (SEM) left atrial diameter was 45 (2) mm, left ventricular end diastolic diameter 69 (2) mm, and left ventricular ejection fraction 22 (1)% in the patient group. Five patients had coronary artery disease and five had idiopathic dilated cardiomyopathy. Two patients had atrial fibrillation. A cardioverter-defibrillator had been implanted in three patients because of sustained ventricular tachycardia or ventricular fibrillation. Drugs consisted of an ACE inhibitor in 10 patients, a diuretic in eight, β acetyldigoxin in seven, nitrates in six, and calcium antagonists in two.

Patients and control subjects did not differ in baseline values of heart rate, ventilation, blood gases, and lung function (table 1). Baseline values of muscle sympathetic nerve activity, expressed as bursts/min and total activity, were higher in the patient group than in the control group.

**Table 2** Effect of CPAP 0, 5, and 10 cm H₂O on muscle sympathetic nerve activity, blood pressure, and ventilation

<table>
<thead>
<tr>
<th></th>
<th>Patients (n=10)</th>
<th>Controls (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSNA (bursts/min)</td>
<td>43 (14)</td>
<td>45 (13)</td>
</tr>
<tr>
<td>MSNA/TA (au)</td>
<td>349 (48)</td>
<td>411 (53)*</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>64 (7)</td>
<td>64 (7)</td>
</tr>
<tr>
<td>Systolic BP (mm Hg)</td>
<td>110 (17)</td>
<td>114 (22)</td>
</tr>
<tr>
<td>Diastolic BP (mm Hg)</td>
<td>65 (8)</td>
<td>70 (11)*</td>
</tr>
<tr>
<td>Respiratory rate (breaths/min)</td>
<td>35 (5)</td>
<td>13 (4)</td>
</tr>
<tr>
<td>Tidal volume (ml)</td>
<td>557 (179)</td>
<td>536 (173)</td>
</tr>
<tr>
<td>P&lt;CO₂ (kPa)</td>
<td>4.93 (0.53)</td>
<td>4.53 (0.67)*</td>
</tr>
<tr>
<td>Oxygen saturation (%)</td>
<td>95.7 (0.6)</td>
<td>96.4 (0.4)*</td>
</tr>
</tbody>
</table>

Values are mean (SEM).

*p < 0.05 vs CPAP 0 (paired t test); **p < 0.05 vs CPAP 5 (paired t test).

au, arbitrary units; BP, blood pressure; MSNA, muscle sympathetic nerve activity; P<CO₂, partial pressure of carbon dioxide; TA, total activity.

Effect of CPAP on muscle sympathetic activity, blood pressure, and heart rate

In both patients and control subjects, there was an increase in muscle sympathetic nerve activity while they were on CPAP, expressed either as bursts/min or as total activity (ANOVA, table 2). The relative increase in muscle sympathetic nerve activity did not differ significantly between the patient and control groups (table 3). The individual changes in muscle sympathetic nerve activity with CPAP in the patients and control subjects are shown in figs 1 and 2. In eight patients, CPAP at 10 cm H₂O increased the number of bursts/min in a range from 2.2% to 57.7% compared with mask breathing. Two patients had a decrease in sympathetic nerve activity while on CPAP 10 cm H₂O (−4.5% and −9%). These two patients did not differ at baseline from the others in sympathetic nerve activity, blood pressure, heart rate, underlying cardiac rhythm, cardiac dimensions, or oxygen saturation. However, they showed a different breathing pattern at baseline, characterised by a high respiratory rate and a low tidal volume, which was completely reversed by CPAP: respiratory rate decreased from 18 (1) breaths/min at baseline to 11 (1) breaths/min at 10 cm H₂O CPAP, while tidal volume increased from 430 (48) ml at baseline to 712 (45) ml (compare with the values for the whole patient group in tables 1 and 2).

In the patients, both systolic and diastolic blood pressure increased during CPAP, while mask breathing (CPAP 0 cm H₂O)

Patients had a higher tidal volume during mask breathing than at baseline, at 447 (128) v 545 (179) ml (p = 0.003). In the control group, breathing with a nasal mask resulted in higher tidal volume (438 (54) v 536 (61) ml; p = 0.002) as well as a higher oxygen saturation (96 (0.5)% v 97.3 (0.3)%; p = 0.02) and a higher partial pressure of CO₂ (5.05 (0.13) v 5.19 (0.13) kPa; p = 0.001) when compared with normal breathing. Breathing with a nasal mask did not influence muscle sympathetic nerve activity, heart rate, or systolic, diastolic, and mean blood pressure in either group, nor did it affect the partial pressure of CO₂ and oxygen saturation in the patient group. Thus any change in these variables during the application of CPAP is compared with mask breathing without CPAP in further analyses (table 2).
HEINDL, DOTZ, KRAHWINKE, ET AL.

GASES

EFFECT OF CPAP ON VENTILATION AND BLOOD GASES

There was no significant change in respiratory rate or tidal volume in patients and control subjects while on CPAP compared with mask breathing (ANOVA, Table 2). The partial pressure of CO₂ was lower during CPAP 10 cm H₂O compared with mask breathing (80 (3) vs 86 (4) mm Hg, p = 0.0009 in the patients; 96 (4) vs 100 (4) mm Hg, p = 0.009 in the control subjects; ANOVA). CPAP induced no change in heart rate in either group.

Table 3  Comparison of CPAP induced changes in patient and control groups

<table>
<thead>
<tr>
<th></th>
<th>Patients (n=10)</th>
<th>Controls (n=10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSNA (%)</td>
<td>12 (6)</td>
<td>20 (9)</td>
</tr>
<tr>
<td>Mean blood pressure (%)</td>
<td>1.1 (0.3)</td>
<td>0.3 (0.2)*</td>
</tr>
<tr>
<td>Oxygen saturation (%)</td>
<td>-12 (3)</td>
<td>-13 (5)</td>
</tr>
<tr>
<td>PCO₂ (%)</td>
<td>100 (4) mm Hg</td>
<td>96 (4) mm Hg</td>
</tr>
</tbody>
</table>

Values are mean (SEM). *p < 0.05 (paired t test).

MSNA, muscle sympathetic nerve activity; PCO₂, partial pressure of carbon dioxide.

There was a significant increase only in diastolic blood pressure in the control subjects (ANOVA, Table 2). Mean blood pressure increased significantly in both groups during CPAP 10 cm H₂O compared with mask breathing (80 (3) vs 86 (4) mm Hg, p = 0.0009 in the patients; 96 (4) vs 100 (4) mm Hg, p = 0.009 in the control subjects; ANOVA). CPAP induced no change in heart rate in either group.

Figure 1  Individual changes of muscle sympathetic nerve activity (MSNA) at baseline, during mask breathing (CPAP 0 cm H₂O), during CPAP 5 and 10 cm H₂O, and during the recovery period in the patients.

Figure 2  Individual changes of muscle sympathetic nerve activity (MSNA) at baseline, during mask breathing (CPAP 0 cm H₂O), during CPAP 5 and 10 cm H₂O, and during the recovery period in the control subjects.

Discussion

The main finding of our study is that short term application of CPAP elicits a modest increase in muscle sympathetic nerve activity in both patients with congestive heart failure and healthy control subjects. Mean blood pressure increased simultaneously in both groups while on CPAP.

The most plausible explanation for the increases in sympathetic activity and blood pressure during CPAP is cardiovascular reflex activation of sympathetic outflow. Arterial baroreceptors in the carotid sinus are probably not involved in the sympathetic activation observed during CPAP because arterial blood pressure increased under these conditions. Any rise in arterial blood pressure increases the transmural pressure of the carotid wall ("unloading" of the carotid receptors), which would have triggered a reflex decrease in muscle sympathetic nerve activity rather than the observed increase.

The aortic baroreflex is more likely to have contributed to the CPAP induced sympathetic activation by the following mechanism: the increased intrathoracic pressure during CPAP decreased the transmural pressure in the aortic arch, thus inducing unloading of the aortic receptors and a reflex increase in muscle sympathetic nerve activity.

Cardiopulmonary baroreceptors—located in the right and left atria and ventricles, in the right and left vein–atrial junctions, and in the pulmonary veins—represent another group of baroreceptors regulating sympathetic outflow.20 Cardiac preload is considered the main determinant of the activity of these volume sensitive stretch receptors. A reduction in venous return and lowering of cardiac filling pressures by lower body negative pressure results in cardiopulmonary baroreceptor unloading and an increase in muscle sympathetic nerve activity in normal subjects.21 It has been shown that...
 mechanical ventilation with continuous posi-
tive pressure or with positive end expiratory
pressure (PEEP) decreases right and left atrial
transmural pressures and right and left ven-
tricular end diastolic transmural pressures.22 23
We do not know the relative roles of the aor-
tic and the cardiopulmonary baroreflex path-
ways in the sympathetic activation observed
during CPAP. We found an increase in muscle
sympathetic nerve activity and mean blood
pressure while heart rate remained unchanged
during CPAP in both healthy subjects and
patients with congestive heart failure. This
suggests that the cardiopulmonary barorecep-
tors play a predominant role in the sympathetic
activation observed during CPAP, as unloading
of these receptors during lower body negative
pressure causes an increase in muscle sympa-
thetic nerve activity without affecting heart rate
and mean arterial pressure.20 The observed
increase in mean arterial blood pressure is
probably a sequel of the sympathetic activation
during CPAP in our study. The unloading of
aortic or cardiopulmonary baroreceptors be-
cause of the increased intrathoracic pressure
during CPAP may override the potential sympapthoinhibitory effect of the increase in
arterial blood pressure (and thus in transmural
pressure in the carotid arteries). This observa-
tion is consistent with the work of Sanders and
colleagues,24 suggesting that the aortic barore-
flex plays a more important role than the
carotid baroreflex in the control of sympathetic
nerve responses in normal human subjects.
Some alternative mechanisms should be
considered when attempting to explain the
increases in muscle sympathetic nerve activity
and blood pressure during CPAP. Changes in
ventilation and blood gases are known to influ-
ence the autonomic nervous system.20 21 CPAP
induces lung inflation and probably stimulates
eroneural activity thereby increasing para-
sympathetic tone and reflexively decreasing
sympathetic tone.18 20 We did not measure
end expiratory lung volume or parasympathetic
activity, and it is possible that parasympathetic
activation with an inhibitory effect on sympa-
thetic activity did occur in our patients and
control subjects. However, sympathetic activa-
tion caused by diminished baroreceptor dis-
charge seems to override any indirect sympath-
oinhibitory effect resulting from altered
ventilation, so that the net effect is a mild to
moderate increase in muscle sympathetic nerve
activity in most patients and control subjects.
We observed an increase in oxygen saturation
in the patient group and a pronounced fall in
end tidal partial pressure of CO2 in both groups
while they were on CPAP. These blood gas
changes are not likely to have contributed to the
CPAP induced increase in sympathetic activity,
as hyperoxia is associated either with no change
in muscle sympathetic nerve activity or with only
a mild decrease,27 28 and hypocapnia is also likely
to induce sympathetic inhibition.29
The finding of higher oxygen saturation dur-
ing CPAP in the patients than in the control
subjects is consistent with current concepts of
lung function in congestive heart failure. CPAP
probably improves the ventilation–perfusion
mismatch present in congestive heart failure
and therefore improved the oxygen saturation
in our patients but not in our control subjects.
No change in PCO2 during short term applica-
tion of CPAP is observed in patients with acute
or chronic heart failure.30 31 We are aware that a
systematic underestimation of the end tidal
PCO2 during CPAP could have occurred in our
investigation.20
Finally, it may be suggested that the experi-
mental situation with mask breathing and appli-
cation of CPAP could have caused mental stress,
leading to sympathetic activation. This is not a
likely explanation for the observed increase in
sympathetic activity in our study, because
patient and control subjects were made familiar
with the nasal mask and with CPAP before
starting the experiment, and breathing with a
nasal mask without application of CPAP did not
cause any change in sympathetic activity. In
addition, heart rate—which is considered as a
sensitive indicator of mental stress—did not
increase during the experiment.33
Consistently with many previous reports, in
our present study patients with congestive
heart failure had higher levels of sympathetic
activity than healthy control subjects matched
for age, sex, and body mass index.18 19 Patients
were on treatment with diuretics, ACE inhibi-
tors, and glycosides, which may explain the fact
that their mean heart rate was not increased in
comparison with the controls.
The finding that positive pressure ventilation
increases muscle sympathetic nerve activity
and blood pressure in healthy subjects is
consistent with previous studies.14 35 However,
the application of 10 cm H2O CPAP for 45
minutes had no effect on sympathetic activity
or blood pressure in the patients with conges-
tive heart failure reported by Naughton and
colleagues.31 Although we used similar inclu-
sion criteria in our study, the patients investi-
gated by Naughton and colleagues tended to be
more obese (body mass index 27.4 (1.4) kg/
m2) and had more restrictive lung function
tests (vital capacity 80 (8)% of predicted), a
slightly higher blood pressure (115/77 mm Hg),
and a higher heart rate (76 (5) beats/min) than
our patients, suggesting that the patient popula-
tions were not comparable in the two studies.
Two patients had a slight decrease in sympa-
thetic activity during CPAP in our study. These
two patients showed a different breathing
pattern at baseline, characterised by a high res-
piratory rate and a low tidal volume which was
completely reversed by CPAP. Rapid shallow
breathing may reflect increased cardiac filling
pressures and pulmonary congestion which
could explain the beneficial effect of CPAP on
ventilation and sympathetic activity in these
two patients.32 There is evidence of an altered
cardiopulmonary reflex pathway in patients
with congestive heart failure and raised pulmo-
nary wedge pressures: isolated deactivation of
the cardiopulmonary baroreceptors (during
lower body negative pressure) has been shown
to cause forearm vasoconstriction in patients
with congestive heart failure and normal
pulmonary wedge pressures, but a paradoxical
forearm vasodilatation in a subgroup of patients with congestive heart failure and raised pulmonary wedge pressures.\(^5\)

**LIMITATIONS**

A limitation of our study is that we did not measure cardiac output changes during CPAP. In normal subjects, CPAP decreases venous return by increasing the intrathoracic pressure and is thus associated with either no change in cardiac output or with a tendency to decrease the output.\(^5\)\(^,\)\(^6\) However, in congestive heart failure with raised cardiac filling pressure, CPAP may increase cardiac output\(^7\)\(^,\)\(^8\) either through a decrease in left ventricular transmural pressure (and thereby left ventricular afterload) or through a decrease in sympathoadrenergic tone or by vasodilatation.\(^9\)\(^,\)\(^10\)

We only investigated the short term effect of CPAP on the sympathetic nervous system. Our results suggest that the favourable haemodynamic effects observed during short term application of CPAP in patients with congestive heart failure\(^1\)\(^–\)\(^8\) are not related to a decrease in sympathetic activity, though there may well be beneficial effects on sympathetic activity during long term treatment with nocturnal CPAP, as proposed by Naughton and colleagues.\(^9\)\(^,\)\(^10\)

Other mechanisms are likely to contribute to sympathetic outflow modulations during long term treatment with CPAP—for example, a reduction in Cheyne-Stokes respiration and an improvement in left ventricular performance. Further studies are needed to determine short and long term benefits and the effects of CPAP on the sympathetic nervous system in patients with stable congestive heart failure.

Supported by the Deutsche Forschungsgemeinschaft (DFG, An 260/1-2).